Articles by Roger Dabbah - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Roger Dabbah

Roger Dabbah

director

Roger Dabbah, PhD, is director of Complex Actives, Information, and Standards Development for USP, 12601 Twinbrook Parkway, Rockville, MD 20852. He is director of the board of the Parenteral Drug Association Foundation for Pharmaceutical Sciences. Dr. Dabbah is a member of Pharmaceutical Technology's Editorial Advisory Board.

Articles
A Quality-Control Guide Fails to Train the Trainer
August 2, 2011

A book about developing quality-control training manuals provides a wealth of information and a dearth of practical help.

An Unfocused Handbook on Environmental Monitoring
October 20, 2010

An expert-panel-written book has surprising shortcomings.

An Unfocused Handbook on Environmental Monitoring
October 2, 2010

An expert-panel-written book has surprising shortcomings.

More Than You Need to Know about Manufacturing Pharmaceutical Proteins
August 2, 2009

The author of a book about biopharmaceutical production includes irrelevant information.

No Excuse for Nonconformance
March 2, 2009

An updated book provides essential information for scientists who monitor microbial quality.

A Guide That Perplexes
August 2, 2008

Despite its flaws, a recent release fills a need for books about pharmaceutical project management.

The Role of USP in the Assessment of Microbiological Quality of Pharmaceuticals
July 1, 2001

USP ensures the microbiological quality of products by way of the development, proposal, and acceptance of general information chapters.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here